Hansa Biopharma
Peter Nicklin has served as the chairman of the Board since July 2022. He has over 30 years of extensive experience and background in the pharmaceutical and healthcare sector in both developed, as well as emerging markets and significant experience in leading global teams. Peter is Chairman of the Board at Tunstall Healthcare, Sciensus, and Versantis. Peter has served as CEO and Member of the Board of Amann Girrbach AG from June 2017 until January 2020. Previously, he held the position of Corporate Vice President and EMEA President of Baxter International, as well as senior executive roles at Bayer Healthcare, Novartis and Bristol-Myers Squibb.
Peter is member of Hansa’s Remuneration Committee, Scientific Committee and U.S. Committee, Independent of Hansa Biopharma and its executive management and Independent of major shareholders of Hansa Biopharma.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Hansa Biopharma
2 followers
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company that leverage its unique enzyme technology to develop innovative and potentially lifesaving and life altering immunomodulating therapies for rare autoimmune conditions, transplant rejection and cancer.